[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366964-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-366964-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","comprehensive-cancer-analysis-reveals-cfh-as-an-immune-related-and-prognostic-marker","Comprehensive cancer analysis reveals CFH as an immune-related and prognostic marker","","Background Complement Factor H (CFH) plays an essential role in innate and adaptive immunity, yet its clinical relevance and underlying immunological mechanisms across different cancers remain unclear and are debated. Methods Pan-cancer evaluation of CFH across 23 tumor types used TCGA, GTEx, TIMER2.0, cBioportal, and HPA, followed by in vitro functional assays (CCK-8, colony formation, wound healing). Results CFH showed dysregulated expression linked to immune infiltration, stage, and immune subtype, and knockdown suppressed proliferation and invasion. Conclusions CFH is a potential prognostic and immune biomarker for tumor immunotherapy.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-cancer-analysis-reveals-cfh-as-an-immune-related-and-prognostic-marker/366964/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-cancer-analysis-reveals-cfh-as-an-immune-related-and-prognostic-marker/366964.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is CFH, and why is it important in cancer immunity?","Question",{"text":63,"@type":64},"CFH (Complement Factor H) is involved in innate and adaptive immunity. The study highlights its potential role in shaping tumor immunity and the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was CFH analyzed across cancers in this study?",{"text":68,"@type":64},"The research assessed CFH across 23 tumor types using TCGA, GTEx, TIMER2.0, cBioportal, and Human Protein Atlas, then performed in vitro experiments to test CFH function.",{"name":70,"@type":61,"acceptedAnswer":71},"What relationships were found between CFH expression and clinical or immune features?",{"text":72,"@type":64},"CFH expression correlated with immune cell infiltration, clinical stage, immune subtype, and indicators such as tumor mutational burden and microsatellite instability.",{"name":74,"@type":61,"acceptedAnswer":75},"What were the experimental findings when CFH was knocked down?",{"text":76,"@type":64},"CFH knockdown inhibited tumor cell proliferation and invasion in vitro, supporting CFH’s functional involvement in cancer progression.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},366964,1790198202,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Zheng et al. BMC Cancer (2026) 26:142 [https://doi.org/10.1186/s12885-025-15491-0](https://doi.org/10.1186/s12885-025-15491-0)  \nBMC Cancer  \nRESEARCH Open Access  \nComprehensive cancer analysis reveals CFH as an immune-related and prognostic marker  \nXingguo Zheng1, Chen Lv 1 and Xiaoju Guo2*  \nAbstract  \nBackground Complement Factor H (CFH) has been reported as an indispensable role in innate and adaptive immunity. Despite increasing interest in CFH, its clinicopathological implications and immunological mechanisms across different cancers remain unclear and are currently under debate.  \nMethods Investigating the function of CFH in 23 tumor types using The Cancer Genome Atlas (TCGA), GenotypeTissue Expression (GTEx), The Tumor Immune Estimation Resource 2.0 (TIMER2 . 0) database, cBioportal, Human Protein Atlas (HPA) . Then using Cell Counting Kit-8 (CCK8) assay, plate colony formation assay, and wound healing assay to detect the biological function of CFH in vitro.  \nResults CFH exhibited dysregulated expression across multiple cancers, with associations observed between its expression levels, immune cell infiltration, clinical stage, and immune subtype. Additionally, CFH was critically involved in shaping the tumor microenvironment and regulating immune responses. The upregulated expression level of CFH was significantly related to tumor-infiltrating immune cells (TICs), tumor mutational burden (TMB), and microsatellite instability (MSI) . Functionally, we found that knockdown of CFH could inhibit the tumor cell proliferation and invasion. Conclusions This study implies the potential prognostic and immunological role of CFH in various cancers, and CFH could act as a biomarker for tumor immunotherapy.  \nKeywords Complement factor h (CFH), Pan-Cancer bioinformatic analysis, Immune cell infiltration, Tumor microenvironment, Cancer cell proliferation  \nIntroduction  \nCancer, characterized by rapid infiltration, is progressing dramatically worldwide and leads to a dominant cause of global mortality [1–3]. Although increasing evidence highlights the tumor microenvironment (TME) as a pivotal driver of tumor progression, the specific pathways and interactions involved warrant further  \n*Correspondence: Xiaoju Guo [gxju9008@163.com](gxju9008@163.com)  \n1Department of Orthopedics, Nanchang First Hospital, Jiangxi 330008, China  \n2Department of Operating Room, Nanchang First Hospital, Jiangxi 330008, China  \nexploration. We have witnessed remarkable advances in cancer immunotherapy targeting TME [4, 5]. Besides, with the continuous advancement of publicly available repositories in recent years, such as the TIMER2.0 dataset, researchers now have expanded resources for comprehensive immune and cancer-related analyses [6], it is possible to discover novel immune therapeutic targets by analyzing pan-cancer genes and comparing connections with clinicopathologic prognosis and associated tumorinfiltrating immune cells. Accumulating evidence indicates that the complement system plays a progressively more prominent role in modulating tumor immunity [7]. Complement component C3b, for instance, can directly recognize and bind to antigenic structures on tumor cells.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence ","cbCaingDk8VOhrcJ","https://ap.wps.com/l/cbCaingDk8VOhrcJ","pdf",9491962,18,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Immune mechanisms of CFH","[{\"question\":\"What is CFH, and why is it important in cancer immunity?\",\"answer\":\"CFH (Complement Factor H) is involved in innate and adaptive immunity. The study highlights its potential role in shaping tumor immunity and the tumor microenvironment.\"},{\"question\":\"How was CFH analyzed across cancers in this study?\",\"answer\":\"The research assessed CFH across 23 tumor types using TCGA, GTEx, TIMER2.0, cBioportal, and Human Protein Atlas, then performed in vitro experiments to test CFH function.\"},{\"question\":\"What relationships were found between CFH expression and clinical or immune features?\",\"answer\":\"CFH expression correlated with immune cell infiltration, clinical stage, immune subtype, and indicators such as tumor mutational burden and microsatellite instability.\"},{\"question\":\"What were the experimental findings when CFH was knocked down?\",\"answer\":\"CFH knockdown inhibited tumor cell proliferation and invasion in vitro, supporting CFH’s functional involvement in cancer progression.\"}]","Comprehensive cancer analysis reveals CFH as an immune-related and prognostic marker | PDF",1790168472,45,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91eb0ce5ed62e427ead9c8822137c3cd.webp",983,1310,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d847d32bdccd9d2cb94585c861cf8181.webp",982,1309,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41aed67040bdc8336aa339ebef87332a.webp",981,1308,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e71c345b751114b3d9f42b118e2b8c79.webp",980,1306]